News & Updates

In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.

Initiation of venetoclax for acute myeloid leukaemia (AML) in the outpatient setting with a pharmacist-led interdisciplinary protocol is both feasible and safe, reports a study.

Chinese patients with pancreatic cancer have a lower incidence of thromboembolism compared with Western populations, and thromboembolism does not affect overall survival (OS), researchers from the Chinese University of Hong Kong (CUHK) have reported.

Diagnoses of invasive cutaneous melanoma in the year 2020 are characterized by thicker, more ulcerated, and more advanced tumours, a recent study has found. Of note, a 2020 diagnosis is not associated with survival.

Cardiopulmonary function (CPF) recovery failure at 6 months after lung cancer surgery appears to be driven by reductions in lung function and moderate-to-vigorous physical activity (MVPA) from baseline to 2 weeks, suggests a study. Baseline PA and dyspnoea are also associated with the inability to recover CPF.